TAI'AN, China, June 22, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that it will present and meet with investors at the Brean Murray, Carret & Co., 2011 Beijing China Growth Conference on June 27, 2011.
Mr. Stanley Lau, China Biologic's President, and Mr. Y. Tristan Kuo, Chief Financial Officer, will present the Company's strategy, products, markets, and outlook on June 27 at 9:20 a.m. in the JW Marriott Hotel Beijing, 83 Jian Guo Road, Chaoyang District, Beijing.
Investors interested in attending the conference and meeting with China Biologic should contact their Brean Murray, Carret representative.
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently one of the leading plasma-based biopharmaceutical companies in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. Please see the Company's website http://www.chinabiologic.com for additional information.
Company Contact: | |
Mr. Y. Tristan Kuo | |
Chief Financial Officer | |
China Biologic Products, Inc. | |
Tel: +86 53 8620 2206 | |
Email: IR@chinabiologic.com | |
